Topic

Feliza Mirasol is the science editor for 

Articles

The collaboration aims to develop precision genetic medicines using ViaNautis’ proprietary polyNaut technology platform.

Lilly Forms Strategic Collaboration with ViaNautis Bio to Develop Novel Genetic Cargo-based Therapeutics

The companies expect to accelerate the clinical development of MRT-6160, a Phase I drug candidate, as well as explore further therapeutic opportunities across multiple indications.

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics

Through the collaboration, Merck will use Mestag’s proprietary RAFT platform to investigate the pathogenic role that fibroblasts play in inflammatory diseases.

Merck and Mestag Therapeutics Partner on Inflammatory Diseases in $1.9 Billion Collaboration

Under the long-term supply agreement, Lonza will manufacture CASGEVY (exagamglogene autotemcel) for Vertex at its facility in Geleen, the Netherlands, and plans to expand manufacturing to Portsmouth, NH, in the United States.

Lonza to Manufacture Commercial Supply of Vertex’s Sickle Cell Disease Gene-Edited Cell Therapy, CASGEVY

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical. 

Merck Plans to Acquire Investigational Bispecific Antibody from Curon Biopharmaceutical in $1.3 Billion Deal

Genentech will leverage Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines to address certain neurodegenerative diseases.

Genentech Licenses Sangamo Therapeutics’ Epigenetic Regulation and Capsid Technologies in Nearly $2 Billion Deal for Genomics Medicines

Under the license agreement, Andelyin Biosciences will expand its AAV Curator Platform by including MyoAAV plasmids developed by Broad Institute of MIT and Harvard.

Andelyn Biosciences Inks License Agreement with Broad Institute of MIT to Expand AAV Platform Offering

With this acquisition, AbbVie gains Cerevel’s clinical-stage assets that complement AbbVie's emerging neuroscience pipeline as well as branded products for treating psychiatric disorders, migraine, and Parkinson's disease.

AbbVie Completes $8.7 Billion Acquisition of Cerevel Therapeutics to Boost Neurological Pipeline

Under the expanded agreement, Univercells and University of Pennsylvania will evaluate certain bioreactors for scalable gene therapy production.

Deals, Development and Manufacturing